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Abstract
Bacteria use secretion systems to export proteins from inside of the bacterium into the
periplasm, extracellular space, or host cell. Within the Mycobacterium genus, the type VII
secretion systems (T7SS) transport products across the unusually thick and waxy
mycobacterial envelope. T7SS are of particular importance because they are involved in the
virulence of pathogenic mycobacteria. Mycobacteria have as many as five distinct T7SS
called ESX systems. ESX-1, 3, and 5, have demonstrated roles in viability and virulence in
certain pathogenic species like M. tuberculosis and M. marinum. Our research focuses on the
ESX-4 apparatus, the ancestral system that gave rise to the other ESX systems. Although
ESX-4 is the smallest, it shares the hallmark characteristics of ESX systems including a
membrane protein complex and predicted secreted substrates containing a WXG100 motif
necessary for secretion. In M. smegmatis, ESX-4 is required for Distributive Conjugal
Transfer (DCT), a form of horizontal gene transfer during which a donor cell transfers
segments of its genome to a recipient cell, which can lead to the transfer of traits such as
antibiotic resistance. However, the mechanism of protein secretion via the ESX-4 system is
still unknown. Through a mycobacterial protein fragment two-hybrid complementation
assay, we will identify protein interactions within the ESX-4 system. As bacterial mRNA is
polycistronic, we will initially examine interactions of proteins encoded on the same mRNA.
These high priority proteins include putative ESX secreted products. Our results will
demonstrate protein-protein interactions relevant to the ESX-4 system of M. smegmatis,
which will allow us to further understand its mechanism of secretion and increase our
knowledge of T7SS.
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Introduction
I.

Mycobacterium tuberculosis in a historic context
a. Current state of Tuberculosis infection
In 2017, there were approximately 10 million new cases of active tuberculosis

infection reported in all countries and age groups. With 1.6 million deaths that year,
tuberculosis is recognized as the leading cause of death from an infectious agent in the world.
Although 83% of cases are successfully treated, tuberculosis is especially concerning due to
the high prevalence of antibiotic resistant strains and health care providers are quickly
running out of viable treatment options. Tuberculosis is caused by infection with a bacterium
called Mycobacterium tuberculosis (Mtb). Understanding the mechanisms and specific
characteristics of M. tuberculosis would enable researchers to create more efficient treatment
options for the millions of affected individuals (“WHO | 10 facts on tuberculosis,” n.d.).

b. History of TB infection and discovery of Mtb
It is thought that the genus Mycobacterium originated more than 150 million years
ago and evidence of infection in humans dates back 3,300 and 2,300 years as written in
documents found in India and China, respectively. Tuberculosis infection can be traced
throughout history, with mentions of the disease as phthisis or consumption in ancient Greek
and Roman documents. After the fall of the Roman Empire, the disease was common in
Europe and was pervasive throughout the Middle Ages. The exact pathological and
anatomical description was created in 1679 by Francis Sylvius in his work Opera Medica,
where he describes the progression of the disease symptoms. Soon after, an Italian health law
was passed that banned consumptives from being treated in public hospitals and established
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designated locations for their treatment, which was the first official reference to the
infectious nature of the disease.
During the 18th century tuberculosis had become an epidemic in Europe, in part due
to the Industrial Revolution and poor social conditions including malnutrition, poorly
ventilated and crowded housing, and primitive sanitation systems. At the beginning of the
19th century, the scientific community was engaged in a debate regarding the origins of the
disease. Some believed that it was infectious, others that it was hereditary, and others that it
was some form of cancer. Throughout the 19th century, various discoveries were made that
pointed towards the infectious nature of the disease which was eventually demonstrated in
1865 by Jean-Antoine Villemin when he injected a rabbit with liquid from a tuberculous
cavity from an individual who had died. The rabbit remained alive and did not display any
symptoms but after an autopsy, extensive demonstrated signs of infection were discovered.
Eventually, scientist Robert Koch was able to isolate the tubercule bacillus after using
methylene blue staining and cultivating the bacillus in animal serum. This was a landmark
discovery and represented a turning point for the scientific community in the search for a
greater understanding of the disease and cure (Barberis et al., 2017)

II.

M. tuberculosis infection
a. Mode of TB transmission
It has now been established that tuberculosis infection is transmitted through

aerosolized droplet infection. When an individual with active tuberculosis infection coughs
or sneezes, droplets are expelled that contain the Mtb bacteria. Infection is transmitted when
an uninfected individual inhales those droplets, thus introducing the bacteria into their
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system. Although diseases like the cold and flu are spread in the same way, TB is not as
contagious and requires prolonged exposure with an infected individual to cause infection.
Additionally, most individuals with healthy immune systems are able to destroy Mtb bacteria
if exposed and do not become infected. Furthermore, not all individuals infected with TB
display symptoms and are contagious. This is known as latent TB infection and most
individuals with latent TB will never develop the active infection (“Tuberculosis (TB) Causes - NHS.”)

b. Populations most affected by TB
Certain populations are at greater risk for infection by TB. Those with compromised
immune systems, particularly due to chemotherapy and HIV infection are at a much higher
risk of infection and death from TB. According to the World Health Organization, TB is the
leading cause of death of people infected with HIV and a person living with HIV is 20 to 30
times more likely to develop an active TB infection (“WHO | 10 facts on tuberculosis,” n.d.).
Additionally, individuals that are very young or very old are at greater risk for active
infection due to their immune systems generally being weaker than healthy adults. People
that live in crowded conditions or that are in poor health because of lifestyle problems such
as drug and alcohol misuse also tend to have weaker immune systems and are thus at higher
risk of infection (“Tuberculosis (TB)—Causes—NHS,” n.d.). In the United States, people
who had experienced homelessness within a year of infection accounted for 4.3% of new
cases in 2017 (Stewart et al., 2018). Another high-risk factor is proximity to individuals
infected with the disease. Since it is contagious, people who live in or have visited countries
or areas with high levels of TB are at high risk. As of 2017, eight countries account for two
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thirds of new cases. India had the greatest number of new cases, followed by China,
Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Within the
United States, the rate of tuberculosis infection was fifteen times higher among non-U.S.born persons compared to U.S.-born persons. The highest TB rate among all racial/ethnic
groups of non-U.S.-born individuals was among Asians with 27.0 cases per 100,000
individuals reported followed by Blacks with 25.0 cases per 100,000 individuals.
For U.S.-born persons, the highest TB rates were reported among Native Hawaiians
and Pacific Islanders with 6.5 cases per 100,000 individuals followed by American Indians
and Alaska Natives with 3.7 cases per 100,000 individuals (Stewart et al., 2018).
Additionally, TB infection is of great concern within migrant populations and those affected
by humanitarian crises. Crises often cause harm to human health either directly through
violence or indirectly through lack of basic necessities like shelter, food, clean water, and
clothing. During humanitarian crises, infectious disease is often the most significant cause of
ill health and in the case of TB, although the incidence will vary based on country
background and epidemiology, the rate of infection will be higher compared to pre-crisis
levels (Zenner, 2017).

III.

M. tuberculosis challenges faced and current state of research
a. Classification of drug resistant TB
The rapid emergence of multidrug resistant TB (MDR-TB), extensively drug resistant

TB (XDR-TB), and totally drug resistant TB (TDR-TB) is of great concern. In 2017, there
were approximately 490,000 cases of MDR-TB and less than a 50% survival rate in patients
that receive the recommended WHO treatment (Tiberi et al., 2018). MDR-TB is caused by
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strains of TB that are resistant to rifampicin and isoniazid, two of the first line anti-TB drugs.
XDR-TB is classified by strains that are resistant to rifampicin, isoniazid, along with
fluoroquinolone and at least one of the injectable second-line drugs. Recently, certain strains
of TB have been discovered that are resistant to all antibiotics available for testing, which is
known as TDR-TB. A better understanding of the mechanisms by which mycobacteria
acquire drug resistance and the action of anti-TB drugs is imperative for the development of
new therapeutics and preventing the increasing development of drug resistance (Palomino &
Martin, 2014).

b. Treatment of TB infection
Treatment of drug susceptible TB runs a course of approximately six months,
beginning with a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol for the
first two months and then rifampicin and isoniazid for an additional four months. Treatment
of MDR-TB consists of an intensive treatment course of at least eight months and includes
four or more second-line drugs with the entire treatment course lasting 20 months. In
addition to being difficult to treat, MDR-TB strains are ten times more transmissible than
drug susceptible strains. XDR-TB intensive treatment is longer than eight months and
includes the use of third-line anti-TB drugs and the total treatment course lasts longer than
MDR-TB. Many studies have linked the increase in drug resistant TB to misdiagnosis and
mismanagement of drug susceptible TB so improving detection of the disease, the creation of
proper treatment plans, and patient adherence to treatment plans are needed to prevent
increasing levels of drug resistant TB (Poce & Biava, 2015). Low patient adherence to
treatment plans is often due to lengthy treatment durations, complex multidrug regimens,
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adverse side effects, and unreliable public health systems and drug availability. Therefore,
the development of more effective and efficient treatment methods is crucial to improving
patient adherence and halting the development of drug resistant TB (Torfs et al., 2019).

c. Mechanisms of drug resistance by Mtb
There are several mechanisms by which M. tuberculosis can develop drug resistance.
The first includes mutations in a gene that would lead to an alteration of the drug target
binding site. For example, resistance to rifampicin is due to a mutation in the gene rpoB that
encodes the β-subunit of RNA polymerase which is the drug target binding site. Rifampin
blocks the exit tunnel for RNA elongation and inhibits the process of transcription so a
mutation to the β-subunit of RNA polymerase could prevent rifampin from successfully
binding and shutting down transcription (Qi et al., 2016). Another mechanism of resistance
includes mutation leading to the loss of the ability to activate a prodrug, or a biologically
inactive compound which can be metabolized in the body to produce a drug. Both isoniazid
and pyrazinamide are prodrugs that require bioactivation and resistance to these drugs are
caused by mutations in the structures responsible for their activation. Without activation,
both drugs are ineffective and will not treat TB.
Certain drug resistant TB strains are able to enzymatically inactivate certain drugs
like penicillin. Mtb has a class of β-lactamases that, when normally expressed, leads to
resistance to penicillin. Lastly, certain strains of Mtb are drug resistant due to the action of
efflux pumps, which are transport proteins involved with the extrusion of toxic substrates,
which include virtually all classes of antibiotics, from within cells to the external
environment (Poce & Biava, 2015). Several strategies are being explored for overcoming
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drug resistance in TB including developing faster diagnostic methods, developing new drugs
that act upon well-known targets, new drugs that act upon new targets, new drug
combinations, and developing inhibitors of drug-modifying enzymes or efflux pumps
(Webber & Piddock, 2003).

d. Developments in TB treatment through the years
The state of TB treatment has been constantly changing and developing for the past
century. In terms of vaccines and prevention, the Bacille Calmette-Guérin (BCG) vaccine is
currently the only available TB vaccine. First used in humans in 1921, the BCG vaccine is a
live attenuated bacterial vaccine derived from M. bovis that was initially isolated in 1902 and
cultured for 13 years until it lost its virulence. There are now approximately 10
manufacturing strains of the vaccine in use and the WHO currently recommends BCG
vaccination of all healthy newborns at birth in countries or settings with a high incidence of
TB infection (“WHO | BCG vaccine,” n.d.). If it cannot be administered at birth, it should be
given at the earliest possible opportunity and is safe to be inoculated with multiple vaccines
at once (“Fact Sheets | Infection Control & Prevention | Fact Sheet—BCG Vaccine | TB |
CDC,” 2018).
Recently there has been trials of new vaccines against active TB infection. In a recent
clinical trial, vaccine candidate M72/AS01E was able to elicit an immune response and
prevent HIV-negative patients diagnosed with latent TB from progressing to active
pulmonary TB for at least three years. Although this vaccine still requires much additional
testing and conformation, these results are promising for the future (Tait et al., 2019). Other
possible treatments focus on targeting novel mycobacterial drug targets like macromolecules
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involved with the structure of the cell wall and protein synthesis, disrupting pathways that
allow for the formation of drug-tolerant bacteria, and the development of host-directed
therapy which would modulate immune responses to target specific pathways and/or reduce
symptoms during infection (Torfs et al., 2019). Other recent developments have included the
creation of new and faster diagnostic methods that are able to detect the presence of Mtb
bacteria as well as any single nucleotide polymorphisms (SNPs) and mutations that are
associated with drug resistance (Poce & Biava, 2015).

IV.

Overview of Mycobacterium genus and M. smegmatis as a research organism
a. Characteristics of Mycobacterium genus
As of December 2016, there are approximately 170 recognized species of

Mycobacteria that vary widely in their ability to cause disease in humans. Some species are
classified as being strict pathogens, some being non-pathogenic, and some being
opportunistic pathogens (Forbes, 2017). Mycobacteria is a genus of bacteria characterized by
their rod shape and the presence of mycolic acids within their cellular envelope (Houben et
al., 2014). Mycolic acids are 2-alkyl, 3-hydroxy long chain fatty acids that, along with
arabinogalactan and peptidoglycan form the bacterial outer membrane, also known as the
mycomembrane (Figure 1).
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Figure 1. Typical mycolic acid structure. Characterized by a shorter a-hydroxy hydrocarbon
chain and a longer b-hydroxy meromycolic hydrocarbon chain. Mycolic acids can vary based
on hydrocarbon length (denoted by a, b, c, d) or by the presence of functional groups at the Y
and X positions (Druszczyńska et al., 2017).
Mycolic acids occur within all examined mycobacterial species to date. Within
mycobacteria, they typically contain 60-90 carbon atoms but a large diversity of chain
lengths and chemical properties exist within the various species (Figure 1) (Marrakchi et al.,
2014). The mycomembrane is a second, hydrophobic membrane that surrounds the
cytoplasmic membrane of mycobacteria. The cell wall elements are involved with several
cellular processes including signaling, virulence, antibiotic resistance, and immune
responses. The thick mycolic acid layer protects the mycobacteria from outside disturbances
like mechanic and chemical stress, desiccation, antimicrobial treatments, and thus allows
them to persist and resist various types of medical treatment (Figure 2) (Houben et al., 2014).
Specifically, the low permeability of the cellular wall to hydrophilic drugs contributes to drug
resistance characteristic of mycobacteria. And as permeability is directly connected to
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fluidity, the longer the chain of the mycolic acids, the less fluid the cell wall, and the less
permeable the cell wall (Druszczynska et al., 2017).

Figure 2. Diagram of the mycobacterial cell wall. The cell wall consists of thin layers of
peptidoglycan and arabinogalactan along with the thick layer of mycolic acids (Brown et al.,
2015).
b. Overview of Mycobacterium pathogenicity
Within the Mycobacterium genus there are pathogenic, non-pathogenic, and
opportunistic pathogen species. A large amount of effort has been dedicated to specifically
identifying and categorizing all the species of mycobacteria due to the increasing number of
infections caused by nontuberculous mycobacteria. In order to properly manage these
infections in a clinical setting, it is imperative to know which specific species of
mycobacteria is causing the infection. Although mycobacteria share various characteristics,
many species are unique, especially in the ways that they interact with a host (Forbes, 2017).
For example, Mycobacterium abscessus is a species of pathogenic nontuberculous
mycobacteria (NTM) that causes skin and soft tissue infections, central nervous system
infections, and serious lung infections in persons with chronic lung diseases like cystic
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fibrosis. M. abscessus is especially difficult to treat due to certain strains developing
antimicrobial drug resistance making it resistant to disinfectants and leading it to cause postsurgical infections (Lee et al., 2015). Treatment of M. abscessus typically requires testing
various antibiotics to see which will effectively treat the infection (“Mycobacterium
abscessus in Healthcare Settings | HAI | CDC,” 2019).
Another species of pathogenic NTM that causes infection in humans is M. bovis.
Most commonly found in cattle and other ungulates like bison, elk, and deer, M. bovis can
cause TB infection in humans (“Fact Sheets | General | Mycobacterium bovis (Bovine
Tuberculosis) in Humans | TB | CDC,” 2018). Although infection with M. bovis is now
uncommon due to the pasteurization of milk and improved disease control within cattle, M.
bovis is still considered a cause of concern in countries outside of the U.S. (Lan et al., 2016).
Understanding the mechanisms and features of these pathogenic mycobacteria is necessary
for designing effective treatment plans especially considering the increasing prevalence of
multidrug resistant mycobacteria.

c. Mycobacterial model organisms and M. smegmatis
Most of the pathogenic species including M. tuberculosis, and M. leprae, (the
bacterium responsible for leprosy), are slow growing and working with them requires a highlevel laboratory safety protocol. M. tuberculosis is a Category 3 human pathogen and
working with Mtb requires a biosafety level three facilities and carries with it the possibility
of exposure. Therefore, substituting other species of mycobacteria as model organisms is
needed. These models are particularly useful in characterizing systems and biochemical
pathways that are conserved throughout mycobacteria. The use of genus-inclusive model
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organisms is validated by recognizing that current antimicrobials have conserved targets in
model organisms. Mycobacterial model organisms can also provide insights into molecular
machines, such as secretion systems that function during virulence (Shiloh & Champion,
2010).
Conveniently, M. smegmatis, a non-pathogenic species of mycobacteria, is used as a
model organism for studying pathogenic mycobacteria because it is fast growing and shares
many genes and characteristics with the pathogenic species (Gray et al., 2016). It is also
easily genetically manipulated and has contributed to the development of plasmids for
mycobacterial transformation and the isolation of M. smegmatis strains that are permissible
to transformation. Ultimately, discoveries made in mycobacterial model organisms are able
to inform future studies in pathogenic mycobacteria and are able to provide a direct
comparison to those studies to demonstrate shared and divergent pathways (Shiloh &
Champion, 2010).

V.

Bacterial secretion systems
a. Overview of bacterial secretion systems
There is much interest in mycobacterial research focused on the mechanisms

associated with protein secretion. Although the layer of mycolic acids surrounding the
cytoplasm acts as a protective barrier from external threats, that barrier makes the secretion
of proteins more difficult. Protein secretion is an essential process for prokaryotic organisms
by which proteins are transported from the cytoplasm of the bacteria out into the
environment, other parts of the cell, or into another host cell (Green & Mecsas, 2016).
Additionally, secreted proteins are often directly associated with virulence mechanisms in
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pathogenic bacteria (Lee, 2001). These proteins can be responsible for promoting attachment
to eukaryotic cells, acquiring resources in an environmental niche, or directly disrupting host
cell function.
There are various types of secretion systems and their mechanisms can depend on a
variety of factors including how many membranes the proteins need to cross and the type of
protein being secreted. Although the discussion of all types of bacterial secretion systems is
outside the scope of this report, understanding the system by which pathogenic bacteria
secrete proteins will allow for the possible development of additional treatments, as the
disruption of secretion systems would likely prevent the bacteria from causing further
infection (Green & Mecsas, 2016).

b. Mycobacterial secretion systems
Mycobacteria utilize specialized mechanisms in order to transport proteins across
their inner membrane and outer mycomembrane. Originally identified within M. tuberculosis
in 2003, these mechanisms are known as Type VII secretion systems (T7SS). The structural
components of T7SS and the secreted substrates are frequently encoded in linked gene
clusters. In total, five different T7SS have been identified in mycobacteria named ESX
systems one through five (ESX-1 through ESX-5). Although each ESX system is unique,
certain characteristics unify the ESX systems across the different species of mycobacteria.
First, ESX systems contain genes that encode for small secreted proteins (~100 amino acids)
that contain a WXG motif (Vaziri & Brosch, 2019). This means that the proteins have a
conserved Trp-X-Gly amino acid sequence pattern that allows the secreted protein to form a
helix-turn-helix structure (Figure 4). Second, ESX systems are identifiable by genes that
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encode for transmembrane proteins which aid in the secretion of substrates. There are certain
transmembrane proteins that are conserved across the different ESX systems and are thus
named Ecc proteins or ESX conserved components (Figure 3) (Famelis et al., 2019). While
the inner-membrane machinery has been explored more extensively, little is known about
how ESX exported proteins are transported from the mycobacterial outer membrane into the
extracellular environment (Vaziri & Brosch, 2019).

Figure 3. Model for T7SS. Esx proteins are secreted as dimers by the T7SS machinery. The
ESX conserved components are denoted EccA through EccE. The channel in the outer
membrane is still yet to be identified (Houben et al., 2014).
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VI.

Protein secretion via ESX secretion systems
a. Characteristics of ESX secreted proteins
Even though there are five total ESX systems, only ESX-3 and ESX-4 are found in

all species of mycobacteria. The ESX-2 and ESX-5 systems are only present in slow-growing
bacteria. Extensive research on the ESX-1 system of M. tuberculosis showed that many of its
substrates require a protein “partner” in order to be co-secreted (Champion et al., 2014). The
co-secreted proteins typically contain the WXG motif which allows them to dimerize with
their partners and form the double helix structure typical of substrates secreted by ESX
systems. The two-helix hairpin secreted proteins are dependent on each other for stability and
form a tight dimer held together by extensive hydrophobic interactions (Figure 4). It is
important to note that these WXG proteins are expressed and secreted by multiple types of
ESX systems in both pathogenic and non-pathogenic bacteria and their functions are still
being defined (Callahan et al., 2010).
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Figure 4. Structures of T7SS substrates EsxA and EsxB. WXG motifs are shown in red and
the secretion signal motif YxxxD/E is shown in orange. (Houben et al., 2014)
b. ESX system functions and variation among species
The same ESX system can also serve a different purpose in different species. For
instance, ESX-1, ESX-3, and ESX-5 have been found to contribute to the virulence of M.
tuberculosis with ESX-1 being responsible for the secretion of the main virulence factors of
M. tuberculosis (Tiwari et al., 2019) and ESX-5 is responsible for the transport of proteins,
cell wall integrity, and full virulence (Bottai et al., 2012). The attenuated strain of M. bovis
utilized in the BCG vaccine does not contain ESX-1, further demonstrating its involvement
in the secretion of virulence factors of mycobacteria (Champion et al., 2014). It would then
be easy to assume then that ESX-1 is responsible for the secretion of virulence factors in all
mycobacteria but M. abscessus, a pathogenic mycobacterium, does not have ESX-1 and its
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virulence factors instead seem to be secreted by ESX-4 (Laencina et al., 2018). The diversity
of functions of the ESX systems within mycobacteria is fascinating and further research is
needed to understand their complexities.
Other than secreting virulence factors, the ESX systems are involved in a variety of
processes such as the regulation of metals, and intracellular communication. ESX-3 has been
confirmed to be involved in iron and zinc metabolism in both metal limited and metal
sufficient conditions in M. tuberculosis (Serafini et al., 2013). One ESX system, ESX- 4, is
particularly interesting due to its importance with a specific form of horizonal gene transfer
(HGT), known as Distributive Conjugal Transfer (DCT) in M. smegmatis (Figure 5). Bacteria
utilize HGT to move genetic material from one organism to another, allowing for genetic
diversification and mitigating the constraints of asexual reproduction (Gray et al., 2013).
Conjugation, a form of HGT, is described as the process by which DNA, usually in the form
of plasmids and integrative conjugal elements, is passed from a donor to recipient bacteria. In
mycobacteria, conjugation transfers chromosomal sequences, not plasmids and thus is a
process by which a donor strain transfers a portion of its genome to a genetically distinct
recipient strain. This process is known as Distributive Conjugal Transfer (DCT) and it
produces mosaic progeny that displays genetic diversity similar to genetic mixing observed
through meiotic recombination of sexual organisms (Figure 6).
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Figure 5. ESX-4 secretion mechanism in M. smegmatis. Ecc proteins are labeled and
proteins EsxU and EsxT are demonstrated as being secreted through the mechanism. The star
denotes secreted protein pairs yet to be confirmed.
Through DCT, certain traits like antibiotic resistance or mutations can be passed
along so understanding how DCT contributes to increasing genetic diversity is essential to
predicting bacterial evolution rates and gene flow through strains. The Derbyshire/Gray Lab
has discovered that a functional ESX-1 system in both donor and recipient, and a functional
ESX-4 system in the recipient, are required for DCT (Gray et al., 2016). Although ESX-4 is
the most ancestral ESX system, much is still unknown about its functions and mechanism of
protein secretion within M. smegmatis.
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Figure 6. Example of the mosaic genome that results from DCT which is represented
by circos plots of recipient chromosomes after DCT. The yellow segments represent the
DNA of the recipient and the blue segments represent segments of DNA received from the
donor. The green segments correspond to a gene that corresponds to antibiotic Kanamycin
resistance (Gray & Derbyshire, 2018).
c. Methods of studying protein interactions in Mycobacteria
With such a diversity of important functions, understanding the mechanism and
function of ESX-4 is vital to understanding Type VII secretion systems as a whole. And part
of understanding its mechanism is knowing how and what proteins secreted by ESX-4
interact and are secreted together. Exploring protein functions is important to understanding
how they function in complexes, play a role in complex pathways, form enzymatic
complexes, and how they are secreted from the cell. Various methods are available to study
protein interactions including co-immunoprecipitation, crystallography, and tandem affinity
purification among others, but these methods require large amounts of data and complex
techniques. The yeast two-hybrid (Y2H) system is a more cost effective and technically
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accessible method that can detect direct interactions between two specific proteins. This is
done by using genetically modified yeast strains that contain a modified reporter gene, which
when transcribed leads to a specific phenotype, usually survival on restrictive growth
medium. The two proteins of interest are fused with either the DNA binding domain (DBD),
referred to as the “bait”, and the activation domain (AD), referred to as the “prey”. If the two
proteins interact, the DBD and AD will interact allowing for the transcription of the reporter
gene and the visualization of the specific phenotype (“Yeast two-hybrid (Y2H) principle,”
n.d.).
Within mycobacteria, a similar technique to Y2H can be used in M. smegmatis called
mycobacterial protein fragment complementation (M-PFC). This technique is useful as it
allows for protein interactions in a native environment and proteins from pathogenic bacteria
can be utilized without concern of accidental lab exposure and virulence. The assay works
through the use of the enzyme DHFR and the antibiotic trimethoprim. A complete and
functional mammalian Dihydrofolate Reductase Recombinant Protein (mDHFR) enzyme
allows for the growth of mycobacteria on plates containing the antibiotic trimethoprim. The
gene fragments of the two proteins of interest are added to plasmids that each contain a
fragment of mDHFR. As the plasmid is transcribed, the protein is made with the fragment of
DHFR attached. If the two proteins of interest interact, the two fragments of mDHFR will be
brought together, made functional, and allow the mycobacteria to grow on trimethoprim
plates (Figure 7).
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Figure 7. Diagram illustrating the principle of the M-PFC. Interacting proteins will bring
together the fragments of mDHFR [FI,2] and [F3], which will result in growth on media
containing trimethoprim. Proteins that do not interact will not bring together the fragments of
mDHFR and no growth will occur (Singh et al., 2006).
VII.

The research problem
The focus of this senior thesis project is on the identification of proteins secreted via

the ESX-4 system within M. smegmatis. In order to determine if certain proteins of interest
interact and are co-secreted by ESX-4, we designed and conducted a mycobacterial protein
fragment two-hybrid complementation assay. A total of seven genes that encode for proteins
secreted by ESX-4 were cloned into two plasmids, pUAB300 and pUAB400. The plasmids
each contain a fragment of mDHFR, which, when complete, confers resistance to the
antibiotic trimethoprim. If the proteins of interest interact, the two fragments of mDHFR will
be brought together and allow M. smegmatis to grow on plates containing trimethoprim.
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Various combinations of proteins were electroporated into M. smegmatis cells, which were
then plated out onto trimethoprim plates and allowed to grow. Growth indicates that the
proteins do interact. Absence of growth indicates that the proteins do not interact. Knowing
the way in which proteins interact and are secreted via the ESX-4 system is especially
important to further understanding the mechanism by which DCT occurs. As it has been
speculated that DCT and conjugation could be responsible for the genomic mosaicism seen
in pathogenic mycobacteria, knowledge regarding the mechanism of the ESX-4, the most
ancestral ESX system, could provide valuable insight (Gray et al., 2013). Identifying the
interacting proteins will allow us to better understand the ESX-4 secretion system and T7SS
within M. smegmatis.
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Materials and Methods
I.

Q5 PCR of genes of interest
A total of seven proteins were identified as possible secreted partners from the ESX-4

system due to the presence of WXG motifs within their structure and their chromosomal
locations near or next to one another in the esx-4 gene locus. These proteins were confirmed
to be present in M. smegmatis through a secretome analysis conducted previously. Two of
these proteins, EsxU (MSMEG_1538) and EsxT (MSMEG_1539), are the primary WXG
secretion substrates of ESX-4. They are similar to EsxA and EsxB from the ESX-1 system in
M. tuberculosis which have been identified as important virulence factors (Figures 9 and 11).
The second protein pair predicted to interact is encoded by the genes MSMEG_1560 and
MSMEG_15750 because both contain WXG motifs and are also localized near each other
(Figures 8 and 11). The last possibly interacting genes are a trio of proteins (MSMEG_1687,
MSMEG_1686, and MSMEG_1685) that are all encoded one right after another within an
operon (Figures 10 and 11). Of the three, 1686 is the largest with an ORF size of
approximately 1 kb while 1685 and 1687 are about a third of that size. It is predicted that a
combination of two or all three proteins will interact.
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Figure 8. Modeled structures of proteins
1560 and 15750. Created using Phyre2
and colored by rainbow from the N to C
terminus.

Figure 9. Modeled structures of
proteins EsxU and EsxT. Created
using Phyre2 and colored by
rainbow from the N to C terminus.

Figure 10. Modeled structures of proteins 1685, 1686, and 1687. Created using Phyre2 and
colored by rainbow from the N to C terminus.
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Figure 11. Visual representation of the location of our seven proteins of interest within the
MKD8 genome.
In order to amplify the genes encoding the proteins of interest, Q5 PCR was
performed. The PCR was performed utilizing gDNA from a specific recipient strain of M.
smegmatis known as MKD8. The New England Biolab protocol was followed for a 50 μL
reaction utilizing 5X Q5 Reaction Buffer, 10 mM dNTP’s, 10 μM forward primer, 10 μM
reverse primer, Q5 High-Fidelity DNA polymerase, 5X Q5 High GC Enhancer, and nuclease
free water was used to fill the reaction up to 50 10 μL. Dimethyl sulfoxide, DMSO, was also
added in order to improve yield and specificity. The standard PCR procedure was followed
utilizing an annealing temperature of 65°C. The PCR products were then visualized and
confirmed using gel electrophoresis. After some preliminary interaction results were reported
between MSMEG_1685 and MSMEG_1686, a new gene fragment was amplified that
contained both genes in order to combine the dual fragment with MSMEG_1687 to see if the
interaction was strengthened with the inclusion of all three proteins. Products were then
purified utilizing the Qiagen PCR purification kit.
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II.

Vector construction and cloning
After purification, each gene fragment and the pUAB 300 and pUAB 400 plasmid

backbones were digested with two enzymes. The fragments that were being cloned into
pUAB 300 were digested with HindIII-HF and BamHI-HF. The fragments that were being
cloned into pUAB 400 were digested with HindIII-HF and MfeI-HF (Figure 12). Digests
were allowed to run for at least two hours or overnight. A small sample of each digest was
then verified utilizing gel electrophoresis and after being confirmed, the digests were
purified.
Each gene fragment was then combined with its corresponding vector and ligated
together following the general ligation protocol for a 15 μL ligation. The ligated plasmid was
then transformed into E. coli stellar cells via heat shock. The plasmid was combined with the
stellar cells and then heat shocked at 42°C in the PCR machine or a water bath for one
minute. Cells recovered on ice and then in 1 mL of SOC broth for an hour. Tubes were then
spun down and then 100 μL of resuspended culture was plated on single antibiotic LB plates
using a glass spreader and allowed to grow overnight. The plasmid pUAB 300 contains a
marker for Hygromycin (Hyg) resistance so the bacteria containing pUAB 300 were grown
on Hyg plates and the plasmid pUAB 400 contains a marker for Kanamycin (Kan) resistance
so the bacteria containing pUAB 400 were grown on Kan plates.
4 mL cultures of terrific broth with added Kan or Hyg antibiotic were then made
using two single colonies from the single antibiotic ligation plates and allowed to grow in a
rotating wheel shaker overnight. Cultures were then miniprepped utilizing the Qiagen
miniprep kit in order to isolate the plasmid. A diagnostic digest was then done with HindIII-
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HF and either BamHI-HF for pUAB 300 or MfeI-HF for pUAB 400 to ensure that the correct
fragment had been inserted into the plasmid.

groEL promoter region

groEL promoter region

Mammalian DHFR subunit

DHFR Fragment FUSED to Linker
ORF-5

ORF 6
Flexible Gly region
742 BamHI (1)
762 HindIII (1)

679 MfeI (1)
706 HindIII (1)

Int

oriM

pUAB300

pUAB400

4913 bp

4720 bp

hygro

kan (aph)

attP

oriE

oriE

Figure 12. Maps of plasmids pUAB 300 and pUAB 400 that were utilized in this assay.
pUAB 300 contains a marker for Hyg resistance and recognition sites for the enzymes
HindIII and BamHI. pUAB 400 contains a marker for Kan resistance and recognition sites
for the enzymes HindIII and MfeI. Protein fragments were cloned into the plasmids between
the enzyme digest sites.

III.

Electroporation into m𝒄𝟐 155 M. smegmatis cells
After the plasmids had been digested and confirmed to have taken up the correct gene

fragment, 500 ng of plasmid was electroporated into m𝑐 $ 155 which is the standard lab strain
of M. smegmatis. All time constants were around 19-22 milli-seconds which is the ideal for
electroporation into M. smegmatis. The cells were then recovered in TSBtween broth for a
minimum of 3 hours or overnight and then plated on TSA plates containing double antibiotic
selection of Hyg and Kan. The cells were plated using a variety of methods including taking
a loopful of the liquid culture, using a glass spreader with 100 μL of culture, or using a glass
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spreader with 100 μL of spun down and resuspended bacterial culture. The plates were then
allowed to grow in the 37 °C incubator for 3-4 days.

IV.

Assay Plating
Plates were poured utilizing 7H10 agar, 10x ADS, and a final concentration of 25

μg/mL trimethoprim. In order to conduct the assay, cultures were made with 4 mL of
TSBtween and 1 μL of Hyg and 1 μL of Kan along with a colony picked from the
electroporation plates. The cultures were allowed to grow overnight or for however long it
took to reach an optical density (O.D.) of around 1 at 6000 nm visible light wavelength. O.D.
was measured using 500 μL of culture in a spectrophotometer. If the cultures were above an
O.D. of 1, the cultures were diluted back with TSBtween until they were an O.D. of 0.7 and
then allowed to grow back to 1. This process was slightly subjective and we moved forward
with plating as long as all the cultures were approximately the same O.D. 1 mL of neat,
undiluted culture was measured out and a dilution series was done by transferring 100 μL of
undiluted culture to 900 μL of TSBtween and then repeating that process down the line until
four dilutions of the original undiluted culture were created. Then, 5 μL of each dilution was
spotted on a TSA plate as the control and a 25 μg/mL Trimethoprim plate. The plates were
then allowed to grow in the 37 °C incubator for 3-5 days and any growth was observed.

Boerboom 32

Results
The first assay done was conducted utilizing EsxU in pUAB 300 and EsxT in pUAB
400. M. smegmatis grew well on the TSA control plate on the left, indicating that the bacteria
used for this assay were viable (Figure 13). The interaction on the top was the combination of
proteins EsxU in pUAB 300 and EsxT in pUAB 400. Our data show there was growth on the
25 μ g/mL trimethoprim plate indicating that the two proteins do interact (Figure 13). The
interaction is strong, with the spotted colonies plated from the higher concentrations of
culture resulting in large, defined colonies. The colonies on the assay plate are larger and
more robust than the colonies on the control plate, indicating that M. smegmatis containing
EsxU in pUAB 300 and EsxT in pUAB 400 were able to grow successfully, even in the
presence of trimethoprim. On the bottom half of the plate, the combination of EsxU in pUAB
300 and EsxU in pUAB 400 was included. It is possible that Esx proteins could selfheterodimerize and be secreted together so same-protein combinations were included in our
assays. Our data demonstrated that this was not the case for EsxU as no colony growth was
observed on the trimethoprim assay plate (Figure 13).

Figure 13. Assay with the trimethoprim (right) and the control TSA (left) plates containing
the combination of EsxU in pUAB 300 and EsxT in pUAB 400 on the top half and the
combination of EsxU in pUAB 300 and EsxU in pUAB 400 on the bottom half.
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A second assay was conducted in order to confirm the EsxU in pUAB 300 and EsxT
in pUAB 400 interaction, along with other protein combinations not yet tested. The first row
consists of our positive control which was plasmids pUAB 100 and pUAB 200. Neither of
these plasmids had any inserted gene fragments but both contained fragments of mDHFR
which is brought together when combined. This positive control grew well on both the
control TSA plate and the trimethoprim assay plate (Figure 14). The second row contains the
combination of the protein pair 1560 in pUAB300 and 15750 in plasmid pUAB400.
Although the colonies grew well on the control plate, no colony growth was observed on the
trimethoprim, indicating that these proteins do not interact. Below that, we have the protein
pair EsxT in pUAB 300 and EsxT in pUAB400. Again, there is a possibility that these
proteins are able to self-heterodimerize and be secreted together so EsxT was included in a
same-protein combination but no colony growth was observed on the trimethoprim plate,
indicating that it does not self-interact. The next row has the EsxU in pUAB 300 and EsxT in
pUAB400. This interaction again had clear, strong colony growth which in this assay, looks
similar to the positive control (Figure 14). According to our data, we can conclude that EsxU
in pUAB 300 and EsxT in pUAB 400 do interact as indicated by strong colony growth on the
trimethoprim plates. And in the last row, we have the combination of 1686 in pUAB 300 and
1685 in pUAB 400. This interaction was weaker than the EsxU and EsxT interaction and the
colonies that grew on the control plate, but 1686/1685 still clearly demonstrated colony
growth (Figure 14).
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Figure 14. Assay with trimethoprim (left) and TSA (right) plates with, going top to bottom,
the positive control, 1560 (300) with 15750 (400), EsxT (300) with EsxT (400), EsxU (300)
with EsxT (400), 1686 (300) with 1685 (400) on the bottom.

The third assay conducted was done in order to fully confirm the interaction between
EsxU and EsxT. The top row of the plates contained the positive control of pUAB 100 and
pUAB 200. Colonies grew well on both the control TSA plate on the left and the
trimethoprim assay plate on the right (Figure 15). The next row down contained the
combination of EsxU in pUAB 300 and EsxT in pUAB 400 that had previously been
confirmed. But in this assay plating the interaction was not displayed and no colony growth
was observed. The next row down contained pUAB 300 and pUAB 400 without any gene
fragments as a negative control and no growth was observed on the trimethoprim assay plate
but strong growth was observed on the control TSA plate. The second to last row contained
the combination of EsxT in pUAB 300 and EsxU in pUAB 400. This combination was done
to make sure that the previously observed interaction would still be present regardless of
which plasmids the gene fragments were cloned into. Strong growth was observed, and the
colonies looked similar to the interaction between EsxU in pUAB 300 and EsxT in pUAB
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400 seen in previous assays (Figures 13, 14, and 15). The last row contained MKD10 cells
without any plasmids electroporated into the bacteria as a last negative control. Growth was
observed on the control TSA plate but not on the trimethoprim assay plate.

Figure 15. Assay with the trimethoprim (right) and TSA (left) plates. Top row contains the
positive control of pUAB 100 and pUAB 200. Next row down contains EsxU (300) and EsxT
(400). Next down contains a negative control with empty pUAB 300 and pUAB 400. Below
is EsxT (300) and EsxU (400). And the last row contains just MKD10 cells which act as
another negative control.
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Discussion
Our two-hybrid approach has preliminarily shown protein-protein interaction between
EsxU and EsxT (Table 1). It demonstrated growth over multiple assay platings and it
consistently grew on selective plates as well as the positive control. There was also
interaction between EsxU and EsxT when the proteins were cloned into each plasmid
indicating that the interaction occurs independent of what plasmid the protein has been
cloned into (Figures 13, 14, 15). The only result that was slightly puzzling is that the
combination of EsxU (300) and EsxT (400) did not grow on the third assay plating (Figure
15). This combination had been demonstrated to grow various times before so it is likely that
there was something wrong with the specific culture that was utilized in this assay plating.
Bacterial strains are sometimes unstable and have to be re-derived or sequence verified. DNA
sequencing had previously been done to confirm that the appropriate gene sequences had
been properly inserted into the plasmids so it is unclear why the final assay did not
demonstrate any interaction. In order to confirm our preliminary results, additional
repetitions done with newly derived bacterial strains and plasmids are necessary. Lastly,
neither combination of EsxU with EsxU and EsxT with EsxT demonstrated any interaction
effect (Figures 13 and 14) so we have preliminary evidence to demonstrate that EsxU and
EsxT do not heterodimerize and that the pair of both proteins are necessary for secretion.
There was a demonstrated interaction between 1686 in pUAB 300 and 1685 in pUAB
400 on the second assay plate which is interesting for a number of reasons (Figure 14). First,
the interaction does not seem to be as strong as the one between the one between Esx U and
Esx T. Although the colonies are smaller, and the colonies spotted from the more diluted
cultures were very small or did not appear, the colonies that did grow were well formed and
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clearly present. Second, it is interesting because proteins 1686 and 1685 are encoded in an
operon of three genes consisting of 1687, 1686, and 1685 in that order (Figure 11). Neither
1686 nor 1685 have the typical double helix structure of an ESX secreted substrate (Figure
10). Out of that operon, 1687 is the only protein that has the clear helix-WXG-helix structure
along with a secretion signal sequence. Our assay indicates that 1686 and 1685 interact and
are able to be secreted as a pair even though they do not contain the typical characteristics of
an ESX substrate. In order to determine if all three proteins interact, a gene fragment was
generated that contains both 1686 and 1685. This gene fragment will be inserted into one of
our plasmids in order to be electroporated with 1687. We predict that the interaction strength
would possibly be increased with the inclusion of 1687 since it is the protein that contains the
secretion signal sequence and it could possibly be necessary for efficient secretion.
Lastly, we have consistent evidence that proteins 1560 and 15750 do not interact.
During the initial trials of the assay, 1560 (300) and 15750 (400) were plated various times as
they were two of the first gene fragments that were successfully cloned and electroporated
into M. smegmatis. These initial trials were done to streamline the assay plating process and
were done on 25 μg/mL trimethoprim plates along with a TSA control plate. This
combination of proteins consistently did not demonstrate any interaction and during the
formal assay plating, they did not interact. 1560 has the typical structure of an ESX secreted
substrate but it does not seem to interact with 15750, which does not have the typical ESX
substrate structure (Figure 8). It is possible that this pair of proteins requires additional
conditions or proteins in order to interact but at this point it does not appear that they interact.
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Table 1. Overview of our preliminary assay results. Protein pairs marked in green have been
demonstrated to interact and protein pairs marked in red have been demonstrated to not
interact.

pUAB300

pUAB400

Esx U

Esx T

Esx T

Esx U

Esx T

Esx T

Esx U

Esx U

1560

15750

1686

1685
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Conclusion

Figure 16. Network of protein interactions that have been tested or that will be tested. The
orange plasmids correspond to pUAB300 and the green plasmids correspond to pUAB400. Red
arrows correspond to proteins that do not interact, green arrows correspond to proteins that do
interact, and yellow arrows are proteins that have been demonstrated to interact. Thickness of
arrows does not correspond to strength of interaction.
From the assays that we were able to conduct, we have received evidence to suggest
that the protein pairs of EsxU/EsxT and 1686/1685 do interact. Along with those positive
interactions, we were able to determine that 1560 and 15750 do not interact and that EsxU
and EsxT do not self-interact (Figure 16). Moving forward, additional repetitions are
necessary to confirm these findings. Additionally, each plasmid containing a gene fragment
will be electroporated in combination with an empty plasmid that does not contain a fragment
to ensure that any growth that is detected is due to the proteins themselves interacting and not
the plasmids. Due to difficulties obtaining the correct gene fragments, not all interactions
were tested so the next steps would be to complete the network of interactions to observe any
other possible interactions. And in the future, we would want to also include interactions with
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the various Ecc proteins encoded within the ESX-4 secretion mechanism since our current
group of proteins could possibly be required for system stability and would interact with the
actual transmembrane proteins themselves.
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